GLA
DNLI icon

Great Lakes Advisors’s Denali Therapeutics DNLI Stock Holding History

Great Lakes Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.73M Sell
145,045
-82,065
-36% -$1.69M 0.03% 298
2026
Q1 		$4.36M Buy
+227,110
New +$4.52M 0.04% 258

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Great Lakes Advisors's DNLI Position: Q2 2026 in Review

Great Lakes Advisors reduced its Denali Therapeutics (DNLI) stake by 36% in Q2 2026, selling an estimated $1.69M and leaving 145,045 shares worth $3.73M. The position accounts for 0.03% of the portfolio, ranked #298.

Great Lakes Advisors first reported a position in DNLI in Q1 2026 and has held it in 2 quarters since. The position peaked at $4.36M in Q1 2026. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Great Lakes Advisors held 145,045 shares of Denali Therapeutics worth $3.73M as of Q2 2026.
  • Great Lakes Advisors sold 82,065 Denali Therapeutics shares in Q2 2026, an estimated $1.69M.
  • Denali Therapeutics made up 0.03% of Great Lakes Advisors's portfolio in Q2 2026, its #298 holding.
  • Great Lakes Advisors first reported a position in Denali Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Great Lakes Advisors's Denali Therapeutics position peaked at $4.36M in Q1 2026.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Great Lakes Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.